Abstract
Importance Cortical lesions contribute to disability in multiple sclerosis (MS) but their impact on regional neurotransmitter levels remains to be clarified.
Objective To test the hypothesis that cortical lesions in MS alter the regional concentrations of the main excitatory and inhibitory neurotransmitters, glutamate and gamma-aminobutyric acid (GABA), in the affected cortex.
Design Prospective, cross-sectional, observational proton MR-spectroscopy (1H-MRS) and structural MRI study at 7T.
Setting Data were collected at a single center between August 2018 and September 2020.
Participants A volunteer sample of 57 MS patients and 38 healthy participants were screened for participation in the study. 50 MS patients and 28 healthy participants were included. In the final cohort, three patients and five healthy participants were excluded due to drop out (n=6) or insufficient data-quality (n=2).
Exposures Two-voxel 7T 1H-MRS covering the right and left sensorimotor hand areas (SM1-HAND) and high-resolution structural brain 7T MRI.
Main outcome Regional concentrations of glutamate and GABA in SM1-HAND and their relation to cortical lesion volume within the MRS voxel.
Results Data from 34 relapsing remitting (RR) and 13 secondary progressive (SP)MS patients (mean +/− standard deviation, 45.1 +/− 12.5 years, 31 female) along with 23 age- and sex-matched healthy participants (44.4 +/− 13 years, 15 female) entered data-analyses. Patient data were pooled to assess the relationship between cortical lesion volume and neurotransmitter levels. Larger cortical lesion volume within SM1-HAND was associated with higher regional glutamate (0.61 +/− 0.21 log(mm3), P=0.005) and lower regional GABA (−0.71 +/− 0.27 log(mm3), P=0.01) concentration. Between-group comparison showed that glutamate concentration within the SM1-voxel was reduced in SPMS patients compared to healthy participants (−0.75 +/− 0.24 mM, P=0.004) and RRMS patients (−0.55 +/− 0.22 mM, P=0.04), while regional GABA levels did not differ among groups.
Conclusion Our results link cortical lesion load in SM1-HAND with regional glutamate and GABA levels in patients with RRMS and SPMS, showing a shift in balance between regional excitatory and inhibitory neurotransmitters towards increased excitation with increasing cortical lesion volume. Between-group comparisons provide preliminary evidence that a progressive disease course may be associated with a decrease in cortical glutamate levels.
Key points Question: How do cortical lesions change the regional metabolic profile in multiple sclerosis?
Findings: This observational cross-sectional study employed voxel-based proton MR-spectroscopy (1H-MRS) of the primary sensorimotor hand areas (SM1-HAND) at ultra-high field (7T) to show that cortical lesions alter regional concentrations of glutamate and gamma-aminobutyric acid (GABA) in patients with multiple sclerosis. We found that higher regional glutamate concentrations were associated with larger regional cortical lesion volume, whereas higher GABA concentrations were associated with lower regional cortical lesion volume.
Meaning: These findings suggest that cortical lesions shift the regional excitation-inhibition balance towards excitation.
Competing Interest Statement
M.A.J.M., M.F.M.M., V.W., S.C. and O.P., have nothing to declare. H.R.S has received honoraria as speaker from Sanofi Genzyme, Denmark and Novartis, Denmark, as consultant for Sanofi Genzyme, Denmark, and Lundbeck AS, Denmark, and as editor-in-chief (Neuroimage Clinical) and senior editor (NeuroImage) from Elsevier Publishers, Amsterdam, The Netherlands. He has received royalties as book editor from Springer Publishers, Stuttgart, Germany and from Gyldendal Publishers, Copenhagen, Denmark. H.L. is inventor on two patent applications with royalty agreement with RWI AB, Lund, Sweden. F.S. has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, H. Lundbeck A/S, Merck, Novartis, Roche and Sanofi Genzyme. His laboratory has received research support from Biogen, Merck, Novartis, Roche and Sanofi Genzyme. J.R.C. has received speaker honoraria from Biogen. M.B., reports personal fees from the Danish Multiple Sclerosis Society, Biogen, Sanofi Genzyme, Biogen, Merck, Novartis, Bristol-Myers Squibb, Roche and non-financial support from Biogen, Roche and Sanofi Genzyme.
Funding Statement
This study was funded by the Danish Multiple Sclerosis Society [A31942; A33409; A35202; A38506], the independent research fund Denmark [9039-00330B], Gangstedfonden [A38060], and Copenhagen University Hospital Amager & Hvidovre. The 7T scanner was donated by the John and Birthe Meyer Foundation and The Danish Agency for Science, Technology and Innovation [0601-01370B]. H.R.S. holds a 5-year professorship in precision medicine at the Faculty of Health Sciences and Medicine, University of Copenhagen, sponsored by the Lundbeck Foundation [R186-2015-2138]. V.W. is supported by the Danish Multiple Sclerosis Society [A40219] and the Lundbeck Foundation [R347-2020-2413]. H.L is supported by the European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme (grant agreement No 804746). S.C has received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 765148.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Committees on Health Research Ethics of the Capital Region of Denmark gave ethical approval for this work (H-17033372)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Pseudonymized data can only be shared with a formal Data Processing Agreement and a formal approval by the Danish Data Protection Agency in line with the requirements of the GDPR.
